News

Clinical Trial Cleared for GPH101: The First Potentially Curative Sickle Cell Disease Therapy

Clinical Trial Cleared for GPH101: The First Potentially Curative Sickle Cell Disease Therapy

The U.S. Food & Drug Administration (FDA) has cleared an investigational new drug (IND) application for the experimental gene editing therapy GPH101 by Graphite Bio to initiate a Phase 1/2…
Blood Supply Challenges & Transfusion Care of Patients With Haemoglobinopathies During COVID-19 Pandemic

Blood Supply Challenges & Transfusion Care of Patients With Haemoglobinopathies During COVID-19 Pandemic

The COVID-19 pandemic has had an impact on blood supply in several countries, jeopardizing the already demanding and often suboptimal care for haemoglobinopathies patients, mainly in developing and low-income countries…
EdiGene Announces Approval in China of its IND Application for CRISPR/Cas 9 Gene Editing Therapy ET-01 in β-thalassaemia

EdiGene Announces Approval in China of its IND Application for CRISPR/Cas 9 Gene Editing Therapy ET-01 in β-thalassaemia

The Center for Drug Evaluation (CDE) of China‘s National Medical Products Administration (NMPA) has recently approved EdiGene’s application for ET-01, an investigational CRISPR-Cas9 gene editing therapy for patients with transfusion dependent β-thalassaemia. This marks the first…
Just Updated: TIF’s Vaccinations & Therapeutic Drugs for COVID-19 Guide

Just Updated: TIF’s Vaccinations & Therapeutic Drugs for COVID-19 Guide

Everything you need to know about the different COVID-19 vaccines, both already available and developing, in one place! Discover our newly updated Guide “Vaccinations & Therapeutic Drugs for COVID-19“, containing…
Iranian Blood Transfusion Organization Newsletter – December 2020

Iranian Blood Transfusion Organization Newsletter – December 2020

The Iranian Blood Transfusion Organization (IBTO) and its most recent activities are featured on TIF’S website.
Blood Under The Microscope Of The European Commission: An Article by TIF’s Executive Director

Blood Under The Microscope Of The European Commission: An Article by TIF’s Executive Director

by Dr Androulla Eleftheriou The European Commission published in October 2019 the Evaluation Report of the European legal framework for quality standards and blood, tissues and cells. This framework is…
THALIA App: The Skilled Digital Assistant of People with Thalassaemia and Sickle Cell Disease

THALIA App: The Skilled Digital Assistant of People with Thalassaemia and Sickle Cell Disease

Committed to continuing efforts to develop useful tools for individuals with thalassaemia and haemoglobin disorders worldwide, TIF introduces a novel mobile health application for patients with thalassaemia and sickle cell…
COVID-19 Vaccines and Haemoglobin Disorders: The Latest Position Statement of the Thalassaemia International Federation

COVID-19 Vaccines and Haemoglobin Disorders: The Latest Position Statement of the Thalassaemia International Federation

In view of the plans made by national health authorities in every country across the world for the widespread vaccination of individuals against the SARS-CoV-2 virus, the Thalassaemia International Federation…
TIF & UNITED Onlus Co-Organizzano il 1° Meeting Associazioni Italiane Sulle Terapie Nuove e Innovative Per le Emoglobinopatie

TIF & UNITED Onlus Co-Organizzano il 1° Meeting Associazioni Italiane Sulle Terapie Nuove e Innovative Per le Emoglobinopatie

Alla luce dei rapidi sviluppi scientifici nel campo della talassemia e dell’anemia falciforme con nuovi farmaci e trattamenti che promettono di rivoluzionare la gestione di queste malattie, la Federazione Internazionale…
Schaltfläche "Zurück zum Anfang"